Details of the Drug

General Information of Drug (ID: DMB4OFL)

Drug Name
Darinaparsin
Synonyms ZIO-101
Indication
Disease Entry ICD 11 Status REF
Hematologic tumour 2B33.Y Phase 2 [1]
Liver cancer 2C12 Phase 2 [1]
Multiple myeloma 2A83 Phase 2 [1]
Peripheral T-cell lymphoma 2A90.C Phase 2 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C12H22AsN3O6S
Canonical SMILES
C[As](C)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N
InChI
InChI=1S/C12H22AsN3O6S/c1-13(2)23-6-8(11(20)15-5-10(18)19)16-9(17)4-3-7(14)12(21)22/h7-8H,3-6,14H2,1-2H3,(H,15,20)(H,16,17)(H,18,19)(H,21,22)/t7-,8-/m0/s1
InChIKey
JGDXFQORBMPJGR-YUMQZZPRSA-N
Cross-matching ID
PubChem CID
11683005
ChEBI ID
CHEMBL94295
CAS Number
69819-86-9
UNII
9XX54M675G
DrugBank ID
DB06179
TTD ID
D03ZME
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT00421213) Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)